Although we demonstrated that the activation of T cell-dependent anti-tumor immunity mediates in large part the effects of PRMT3 KO or PRMT3 inhibition in HCC progression in multiple model systems, we also observed a significant increase in the total number of B cells and a significant decrease in monocytes and macrophages in Prmt3-KO Hepa1-6 tumors (Fig. 3V). This evidence concerns the gene PRMT3 and neoplasm.